TUSSIONEX PENNKINETIC Drug Patent Profile
✉ Email this page to a colleague
When do Tussionex Pennkinetic patents expire, and when can generic versions of Tussionex Pennkinetic launch?
Tussionex Pennkinetic is a drug marketed by Ucb Inc and is included in one NDA.
The generic ingredient in TUSSIONEX PENNKINETIC is chlorpheniramine polistirex; hydrocodone polistirex. There are twenty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the chlorpheniramine polistirex; hydrocodone polistirex profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TUSSIONEX PENNKINETIC?
- What are the global sales for TUSSIONEX PENNKINETIC?
- What is Average Wholesale Price for TUSSIONEX PENNKINETIC?
Summary for TUSSIONEX PENNKINETIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Patent Applications: | 21 |
| What excipients (inactive ingredients) are in TUSSIONEX PENNKINETIC? | TUSSIONEX PENNKINETIC excipients list |
| DailyMed Link: | TUSSIONEX PENNKINETIC at DailyMed |
Recent Clinical Trials for TUSSIONEX PENNKINETIC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mallinckrodt | Phase 1 |
Paragraph IV (Patent) Challenges for TUSSIONEX PENNKINETIC
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| TUSSIONEX PENNKINETIC | Extended-release Capsules | chlorpheniramine polistirex; hydrocodone polistirex | 8 mg/10 mg and 4 mg/5 mg | 019111 | 1 | 2004-09-10 |
US Patents and Regulatory Information for TUSSIONEX PENNKINETIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | TUSSIONEX PENNKINETIC | chlorpheniramine polistirex; hydrocodone polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 019111-001 | Dec 31, 1987 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TUSSIONEX PENNKINETIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ucb Inc | TUSSIONEX PENNKINETIC | chlorpheniramine polistirex; hydrocodone polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 019111-001 | Dec 31, 1987 | ⤷ Subscribe | ⤷ Subscribe |
| Ucb Inc | TUSSIONEX PENNKINETIC | chlorpheniramine polistirex; hydrocodone polistirex | SUSPENSION, EXTENDED RELEASE;ORAL | 019111-001 | Dec 31, 1987 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TUSSIONEX PENNKINETIC
See the table below for patents covering TUSSIONEX PENNKINETIC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 71886 | LIQUID PROLONGED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING IONIC CONSTITUENTS | ⤷ Subscribe |
| Ireland | 841201 | ⤷ Subscribe | |
| Canada | 1221632 | COMPOSES PHARMACEUTIQUES LIQUIDES A LIBERATION LENTE CONTENANT DES ELEMENTS IONIQUES (LIQUID PROLONGED RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING IONIC CONSTITUENTS) | ⤷ Subscribe |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
